- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00432887
Experimental Studies of the Effects of Caffeine on Glucose Regulation
Caffeine and Glucose Regulation
This project contains experimental studies of the effects of the drug caffeine on glucose regulation in adults who have Type 2 diabetes. In our experiments, we are testing the hypothesis that moderate amounts of caffeine exaggerate the abnormal increases in glucose and insulin observed after meals in patients with type 2 diabetes. On separate study days subjects receive standard meals after taking capsules containing either caffeine or an inactive placebo. We measure levels of glucose, insulin, and other chemicals in blood samples drawn over the next 3 hours. In a separate study, we use continuous glucose monitoring to measure glucose levels during everyday activities on days when subjects receive caffeine or placebo.
These studies do not involve clinical treatment or disease management. However, we hope to learn whether a very popular drug impairs the clinical management of a common disease.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Pilot results suggest that caffeine, the most commonly used drug in the world, may interfere with postprandial glucose metabolism by increasing insulin resistance and/or by stimulating hepatic glucose production. This effect could have serious clinical implications for coffee drinkers who have type 2 diabetes. Early results suggest caffeine exaggerates the postprandial hyperglycemia and hyperinsulinemia present in these patients.
The experimental (non-treatment) studies in this project include double-blind placebo-controlled cross-over laboratory tests of glucose tolerance in groups of type 2 diabetic patients and prediabetic volunteers who are coffee drinkers.
The lab studies test the hypothesis that caffeine (vs. placebo) increases postprandial insulin responses and results in a potentiation of glucose responses in the type 2 group.
An ambulatory study examines the effects of caffeine administration on glucose levels during everyday activities in the natural environment. This study uses a double-blind placebo-controlled cross-over design. Ambulatory glucose data are collected with a MiniMed CGMS sensor and recorder worn for 72 hours. Caffeine and placebo are administered on separate days. Average glucose levels and glucose responses to meals are compared across treatment days within subjects.
Study Type
Enrollment
Phase
- Early Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion criteria:
- 6 months or longer history of type 2 diabetes
- treatment by diet, exercise, or oral medication
- current daily consumption of 2 or more cups of coffee
- BMI >21kg/M2 and < 45kg/M2
Exclusion criteria:
- Required use of insulin
- Current cigarette smoking
- Current use of medications that impact glucose metabolism
- Pregnancy
- Other major medical disorders
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
glucose tolerance
|
insulin resistance
|
postprandial glucose and insulin
|
fasting glucose and insulin
|
Secondary Outcome Measures
Outcome Measure |
---|
blood pressure
|
cortisol
|
epinephrine
|
norepinephrine
|
plasma caffeine concentration
|
Collaborators and Investigators
Investigators
- Principal Investigator: James D. Lane, Ph.D., Duke University
Study record dates
Study Major Dates
Study Start
Study Completion
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Purinergic Antagonists
- Purinergic Agents
- Phosphodiesterase Inhibitors
- Purinergic P1 Receptor Antagonists
- Central Nervous System Stimulants
- Caffeine
Other Study ID Numbers
- DK67486 (completed)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Mannkind CorporationTerminatedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Griffin HospitalCalifornia Walnut CommissionCompletedDIABETES MELLITUS TYPE 2United States
-
Scripps Whittier Diabetes InstituteSan Diego State UniversityCompletedType 2 Diabetes Mellitus (T2DM)United States
-
RWTH Aachen UniversityBoehringer IngelheimCompletedDiabetes Mellitus Type 2 (T2DM)Germany
-
US Department of Veterans AffairsAmerican Diabetes AssociationCompletedType 2 Diabetes MellitusUnited States
-
Dexa Medica GroupCompletedType-2 Diabetes MellitusIndonesia
-
AstraZenecaNot yet recruiting
-
Daewoong Pharmaceutical Co. LTD.Not yet recruitingT2DM (Type 2 Diabetes Mellitus)
-
Zhongda HospitalRecruitingType 2 Diabetes Mellitus (T2DM)China
Clinical Trials on caffeine administration
-
State University of New York at BuffaloCompleted
-
NICHD Neonatal Research NetworkEunice Kennedy Shriver National Institute of Child Health and Human Development...Active, not recruitingApnea of PrematurityUnited States
-
NobelpharmaCompleted
-
Morten Hostrup, PhDActive, not recruiting
-
Universidad Francisco de VitoriaUniversidad de Granada; Universidad Rey Juan Carlos; Camilo Jose Cela UniversityCompleted
-
University of LjubljanaCompletedHeart Rate Variability | Newborn | Caffeine | Apnoea of NewbornSlovenia
-
Hospital de Clinicas de Porto AlegreRecruitingMechanical Ventilation Complication | Caffeine | Ventilator Lung; NewbornBrazil
-
Universidad de ZaragozaRecruitingFatigue | Injuries | Caffeine | Soccer | Females Xy | Biomechanical ParametersSpain
-
University Hospital Inselspital, BerneCompletedPlacebo | Caffeine and Carbohydrate | Carbohydrate OnlySwitzerland
-
Southern Illinois University CarbondaleCompleted